The present invention relates to the dibenzoazulene compounds represented by
formula I as well as to their pharmaceutical preparations for the inhibition of
tumor necrosis factor alpha (TNF-) and interleukine 1 (IL-1) in mammals
at all diseases and conditions where these mediators are excessively secreted.
The compounds of the present invention also demonstrate an analgetic action and
can be used to relieve pain.
